유바이오로직스
Financials
Valuation Metrics
유바이오로직스's Market Cap is ₩2886B. At end of 2025 it was ₩4130B. Ranked #634 of 2,410 in KR market (top 26%), #264 of 1,631 on KOSDAQ (top 16%), #69 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 30%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 288.65B KRW | KR#634/2,410 Sec#69/231 |
| Revenue | 122.31B KRW | KR#1,302/2,410 Sec#82/231 |
| Net Income | 29.00B KRW | KR#576/2,410 Sec#34/231 |
| Total Assets | 240.23B KRW | KR#1,170/2,410 Sec#83/231 |
| Net Assets | 175.36B KRW | KR#1,031/2,410 Sec#71/231 |
| Employees | 353 | KR#685/2,410 Sec#60/231 |
| Value | ||
| P/E | 9.96x | KR#852/2,410 Sec#42/231 |
| P/B | 1.65x | KR#1,862/2,410 Sec#135/231 |
| P/S | 2.36x | KR#1,917/2,410 Sec#113/231 |
| EV/EBITDA | 6.12x | KR#346/2,410 Sec#10/231 |
| FCF Yield | 15.10% | KR#464/2,410 Sec#12/231 |
| Profitability | ||
| ROE | 16.54% | KR#253/2,410 Sec#14/231 |
| ROA | 12.07% | KR#186/2,410 Sec#17/231 |
| Op. Margin | 35.39% | KR#36/2,410 Sec#8/231 |
| Revenue Growth | -17.76% | KR#2,089/2,410 Sec#191/231 |
| Earnings Growth | -39.25% | KR#1,017/2,410 Sec#66/231 |
| Financial Health | ||
| Debt Ratio | 36.99% | KR#728/2,410 Sec#88/231 |
| Total Debt | 0 KRW | KR—/2,410 Sec—/231 |
| FCF | 43.57B KRW | KR#330/2,410 Sec#19/231 |
| Cash | 23.67B KRW | KR#1,145/2,410 Sec#78/231 |
| Current Ratio | 3.97x | KR#385/2,410 Sec#58/231 |
| Net Debt/EBITDA | -0.55x | KR#479/2,410 Sec#29/231 |
| Performance | ||
| 1Y Return | -35.63% | KR#1,649/2,410 Sec#134/231 |
| 1M Return | -5.92% | KR#928/2,410 Sec#92/231 |
| From 52W High | -55.08% | KR#1,447/2,410 Sec#117/231 |
| 1Y MDD | -54.75% | KR#1,170/2,410 Sec#97/231 |
| Trading | ||
| Volume | 63,900 shares | KR#1,000/2,410 Sec#99/231 |
| Trading Value | 506.7M KRW | KR#909/2,410 Sec#98/231 |
| Foreign Own. | 6.19% | KR#714/2,410 Sec#63/231 |
| Per Share | ||
| EPS | 798 KRW | KR#811/2,410 Sec#58/231 |
| BPS | 4,824 KRW | KR#1,534/2,410 Sec#111/231 |
Company Info
Established in 2010 and listed on KOSDAQ in 2017, this company is a specialized venture in vaccine manufacturing and biopharmaceutical contract research and manufacturing. It operates vaccine businesses, supplying 'Euvichol-S' to UNICEF and others, and provides biopharmaceutical CRMO services, with first and second factories and a research institute in Chuncheon. By expanding its cholera vaccine facilities, the company has established an annual production system of up to 90 million doses. It aims to become a global vaccine company through the development of diverse vaccine pipelines. Eubiologics is headquartered in Gangnam-gu, Seoul Special City.